Putting up a Fight

Cosmetic_Injection_Battle_Derma_Blog_May09.jpg Less than a week since word has leaked about the arrival of a Botox competitor, Allergen CEO and top executives are defending their product and brand publicly. Last week Dysport became FDA approved in the US and will soon be making an appearance in the cosmetic dermatology and wrinkle-remover industry. The Orange County based company has relied upon Botox injections as it's primary money-maker, and so a commercially viable competitor may be detrimental to profit and reputation in a very fickle industry. According to Forbes Allergen CEO said, "Each of these botulinum toxins behaves in practice quite differently," Allergan Chief Executive David Pyott said in an interview with the Associated Press. "We've said for quite a while that switching from one to another is like saying 'I'm going to stop speaking English and start talking to you in German.'" Pyott stressed that Botox and Dysport are not interchangeable because the drugs are dosed and injected differently." Many are worried that the cosmetic dermatology industry will fall victim to even more of a downturn, as many are cutting costs and the perks of their previous expendible budgets. However some of the first reported cost-cuts are with elective procedures much like facial fillers.
Have specific questions?
ASK A DOCTOR

All Article Categories

Before & After Photos

Suggested Doctors

Recently Asked Questions